Three years after Common Sensing revealed its prototype for a connected sensor for the caps of disposable insulin pens to measure insulin dosages, the Cambridge-based digital health startup ‘s technology is the focus of a study carried out by principal investigators at the Joslin Diabetes Center. Common Sensing President and Co-founder James White described the study, in which the device company has partnered with Sanofi-Aventis and Dexcom, in a phone interview with MedCity News.
The challenge Common Sensing seeks to address is to provide clinicians with greater insights into their patients’ insulin use between office visits. More than one-third of Type 2 diabetic insulin users have adherence issues, costing roughly $2,500 per user.
